Navigation Links
FDA clears test developed in partnership with VCU researcher
Date:5/22/2012

RICHMOND, Va. (May 22, 2012) The Food and Drug Administration has approved a new test to help physicians diagnose a group of rare cell disorders. The test, or assay, was developed by an expert at Virginia Commonwealth University in the field of mast cells.

Lawrence Schwartz, M.D., Ph.D., chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas Professor of Medicine at VCU, has spent more than 30 years researching mast cells. These cells are vital to the inflammatory process within the body and may play protective roles in wound healing and fighting infections.

"When a mast cell is triggered, it releases several strong chemicals into the body, including histamine and tryptase. Histamine causes itching, swelling, wheezing and sneezing and other signs and symptoms of allergic reactions," said Schwartz.

Mastocytosis, a group of rare chronic disorders found in both children and adults, is caused by the presence of too many of these mast cells in the body. If there are too many mast cells, the increased burden of chemicals released from these cells can cause several symptoms that range in intensity from mild to severe.

Because mast cells play a role in allergic reactions, the symptoms of mastocytosis are often similar to an allergic reaction. However, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The FDA has cleared ImmunoCAP Tryptase, a new diagnostic assay, to measure the level of tryptase in the blood as an aid in the diagnosis of systematic mastocytosis. A persistently elevated baseline level of tryptase is an indication of possible mastocytosis.

"A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool," said Schwartz.

VCU first licensed the assay in 1993 to Pharmacia, now named Thermo Fisher Scientific Inc. The assay has one FDA-approved application helping to diagnose mastocytosis and several potential applications, including the diagnosis of systemic anaphylaxis, the prediction of increased risk for future episodes of severe anaphylaxis and use by medical examiners to evaluate cause of death.

"When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death," said Schwartz.


'/>"/>
Contact: Frances Dumenci
fdumenci@vcu.edu
804-828-7701
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
2. FDA clears biomarker test for ovarian cancer
3. Researchers find process that clears cholesterol and could reverse major cause of heart attack
4. Flightless mosquitoes developed to help control dengue fever
5. New tool developed to help guide pancreatic cyst treatment
6. Innovative Technology Developed at AGH Accurately Monitors Healthcare Professionals' Handwashing Practices, Study Shows
7. Innovative Motorized and Mobile Medical Procedure Table Developed By MTI, Inc.
8. New scanning technology developed in £7M research center
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Human clinical trial of NIH-developed dengue vaccine begins
11. New diabetes risk assessment developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2018)... ... December 14, 2018 , ... OKC dentist , Dr. Grace ... most patients do refer to Dr. Grace Jun as “Dr. Grace” the name change ... in November 2018, one year after Dr. Grace’s initial opening. While changing the office ...
(Date:12/14/2018)... ... ... Becker's Hospital Review is pleased to welcome Super Bowl MVP Quarterback, Fox NFL ... Brown; and Founder of KevinMD.com Kevin Pho, MD, as celebrity keynotes for its Health ... the Swissotel in Chicago. The event will include eight keynote speakers and more than ...
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... improves patient visibility, operational efficiency and financial outcomes, introduced new enhancements to its ... quality care and financial leadership, rather than technology and screen time. , ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... Major Arena Soccer League becoming the official turf provider of the MASL. ... turf system available. The indoor product FastGrass™ allows athletes to showcase their skills ...
(Date:12/13/2018)... ... December 13, 2018 , ... HDAP now ... and approachable in their community. Delia Associates created a solid and scalable platform ... dealing with substance abuse in the greater Hunterdon County area. The nonprofit’s treatment ...
Breaking Medicine News(10 mins):
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... speed, it’s essential that new and established organizations, as well as top talent, ... the potential risks that accompany them. , Through years of working hand-in-hand ...
(Date:12/13/2018)... ... 13, 2018 , ... Women’s Excellence is pleased to announce ... GE Voluson E6 ultrasound to provide superior imaging, resolution, and 3D/4D imaging. , ... forefront of innovation and technological offerings to our patients. Equipment continues to ...
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... Review 10th Annual Meeting April 1 to 4, 2019, at the Hyatt Regency ... system executives speaking as well as 4,200-plus attendees. In attendance will be the ...
Breaking Medicine Technology: